Italia markets open in 6 hours 6 minutes

Biocartis Group NV (0R72.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,7340+0,0143 (+0,83%)
Alla chiusura: 04:40PM GMT
Schermo intero
Chiusura precedente1,7197
Aperto1,7197
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno1,7200 - 1,7200
Intervallo di 52 settimane1,7200 - 1,7200
VolumeN/D
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,51
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

    PRESS RELEASE - REGULATED INFORMATION 31 January 2023, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 31 January 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of January 2023 a further portion of receivables due by the Company to Highbridge under the senior secured 'Facility Agreement' (as amended from time to time) ("First Lien Loan Agreement") conclud

  • GlobeNewswire

    Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES

    PRESS RELEASE: REGULATED INFORMATION17 January 2023, 17:40 CET BIOCARTIS MEETS 2022 KEY OBJECTIVES Mechelen, Belgium, 17 January 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that the Company has achieved its 2022 key business objectives focused on three performance indicators: Idylla™ product revenues, gross margins on product sales and operating cash burn. Based on non-audited numbers for 2022, Biocar

  • GlobeNewswire

    Press release Biocartis Group NV: Completion of Comprehensive Recapitalization Transactions

    PRESS RELEASE: REGULATED INFORMATION16 January 2023, 17:40 CET Completion of Comprehensive Recapitalization Transactions Mechelen, Belgium, 16 January 2023 –Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART) is pleased to announce that the final steps in the previously announced comprehensive recapitalization transactions have been completed today. The initial holders of the Company's 4.50% new second lien secured convertible